Umair Mahmood, Andrew Bang, Yu-Hui Chen, Raymond H Mak, Jochen H Lorch, Glenn J Hanna, Mizuki Nishino, Claire Manuszak, Emily M Thrash, Mariano Severgnini, Matthew Sanborn, Vishwajith Sridharan, Danielle N Margalit, Roy B Tishler, Paul M Busse, Henning Willers, Harvey J Mamon, Hyung-Jin Yoo, Sara I Pai, Lori J Wirth, Robert I Haddad, Nicole G Chau, Jonathan D Schoenfeld
PURPOSE: We evaluated the safety and efficacy of pembrolizumab (pembro) ± radiation therapy (RT) in a phase 2 study among patients with progressive, metastatic adenoid cystic carcinoma (ACC). METHODS AND MATERIALS: Eligible patients had metastatic ACC with progression within the last year and ≥1 measurable lesion. Patients were randomized to pembro alone or with RT to 30 Gy in 5 fractions (pembroRT). The primary endpoint was objective response rate outside the RT field...
January 1, 2021: International Journal of Radiation Oncology, Biology, Physics